377 related articles for article (PubMed ID: 16564617)
1. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.
Pang R; Poon RT
Cancer Lett; 2006 Oct; 242(2):151-67. PubMed ID: 16564617
[TBL] [Abstract][Full Text] [Related]
2. Vascular changes in hepatocellular carcinoma.
Yang ZF; Poon RT
Anat Rec (Hoboken); 2008 Jun; 291(6):721-34. PubMed ID: 18484619
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature.
Kaseb AO; Hanbali A; Cotant M; Hassan MM; Wollner I; Philip PA
Cancer; 2009 Nov; 115(21):4895-906. PubMed ID: 19637355
[TBL] [Abstract][Full Text] [Related]
4. New strategy of antiangiogenic therapy for hepatocellular carcinoma.
Wu XZ
Neoplasma; 2008; 55(6):472-81. PubMed ID: 18999874
[TBL] [Abstract][Full Text] [Related]
5. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
6. Regulation of angiogenesis by Id-1 through hypoxia-inducible factor-1alpha-mediated vascular endothelial growth factor up-regulation in hepatocellular carcinoma.
Lee TK; Poon RT; Yuen AP; Ling MT; Wang XH; Wong YC; Guan XY; Man K; Tang ZY; Fan ST
Clin Cancer Res; 2006 Dec; 12(23):6910-9. PubMed ID: 17145808
[TBL] [Abstract][Full Text] [Related]
7. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma.
Mitsuhashi N; Shimizu H; Ohtsuka M; Wakabayashi Y; Ito H; Kimura F; Yoshidome H; Kato A; Nukui Y; Miyazaki M
Hepatology; 2003 May; 37(5):1105-13. PubMed ID: 12717391
[TBL] [Abstract][Full Text] [Related]
8. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha.
Wada H; Nagano H; Yamamoto H; Yang Y; Kondo M; Ota H; Nakamura M; Yoshioka S; Kato H; Damdinsuren B; Tang D; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Nakamori S; Sakon M; Dono K; Wakasa K; Monden M
Liver Int; 2006 May; 26(4):414-23. PubMed ID: 16629644
[TBL] [Abstract][Full Text] [Related]
9. The molecular mechanism underlying angiogenesis in hepatocellular carcinoma: the imbalance activation of signaling pathways.
Zhao ZC; Zheng SS; Wan YL; Jia CK; Xie HY
Hepatobiliary Pancreat Dis Int; 2003 Nov; 2(4):529-36. PubMed ID: 14627514
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma.
Poon RT; Chung KK; Cheung ST; Lau CP; Tong SW; Leung KL; Yu WC; Tuszynski GP; Fan ST
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4150-7. PubMed ID: 15217952
[TBL] [Abstract][Full Text] [Related]
12. Rac activation is associated with hepatocellular carcinoma metastasis by up-regulation of vascular endothelial growth factor expression.
Lee TK; Poon RT; Yuen AP; Man K; Yang ZF; Guan XY; Fan ST
Clin Cancer Res; 2006 Sep; 12(17):5082-9. PubMed ID: 16951224
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
Li WC; Ye SL; Sun RX; Liu YK; Tang ZY; Kim Y; Karras JG; Zhang H
Clin Cancer Res; 2006 Dec; 12(23):7140-8. PubMed ID: 17145839
[TBL] [Abstract][Full Text] [Related]
14. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness.
Sergio A; Cristofori C; Cardin R; Pivetta G; Ragazzi R; Baldan A; Girardi L; Cillo U; Burra P; Giacomin A; Farinati F
Am J Gastroenterol; 2008 Apr; 103(4):914-21. PubMed ID: 18177453
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma.
Hira E; Ono T; Dhar DK; El-Assal ON; Hishikawa Y; Yamanoi A; Nagasue N
Cancer; 2005 Feb; 103(3):588-98. PubMed ID: 15612021
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis and anti-angiogenesis in hepatocellular carcinoma.
Ribatti D; Vacca A; Nico B; Sansonno D; Dammacco F
Cancer Treat Rev; 2006 Oct; 32(6):437-44. PubMed ID: 16870349
[TBL] [Abstract][Full Text] [Related]
17. [Hypoxia in hepatocellular carcinoma].
Myung SJ; Yoon JH
Korean J Hepatol; 2007 Mar; 13(1):9-19. PubMed ID: 17380070
[TBL] [Abstract][Full Text] [Related]
18. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma.
Wu XZ; Xie GR; Chen D
J Gastroenterol Hepatol; 2007 Aug; 22(8):1178-82. PubMed ID: 17559361
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma.
Kolev Y; Uetake H; Iida S; Ishikawa T; Kawano T; Sugihara K
Ann Surg Oncol; 2007 Oct; 14(10):2738-47. PubMed ID: 17687613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
